LANTUS® basal insulin + oral diabetes medications (OADs) lowered
A1C in more than 5000 patients switched from premix insulin ± OADs
10
Not an actual patient.
|
For type 2 diabetes patients with characteristics similar to the patients studied:
- Mean duration of diabetes: 8.6 (± 6.1) years
- Mean BMI: 28.4 (males); 29.0 (females)
- Mean A1C: 8.3% (± 1.2%)
|
From Hammer and Klinge.10
Switching patients from premix insulin to LANTUS®, a long-acting (basal) insulin,
+ oral diabetes medications (OADs) improved glycemic control
10
From an observational study documenting the effect of switching from premix insulin
(±OADs) to LANTUS® + OADs in 5045 poorly controlled type 2 patients in
everyday practice.
From Hammer and Klinge.10
- Mean FBG reduction of 54 mg/dL [178 ± 48 to 124 ± 26 mg/dL]
- Mean postprandial blood glucose reduction of 55 mg/dL [195 ± 50 to 140 ± 27 mg/dL]
Low incidence of hypoglycemia 10
- 16 reported incidences in 6560 patients
IMPORTANT SAFETY INFORMATION FOR LANTUS®
LANTUS® is indicated for once-daily subcutaneous administration, at the same
time each day, for the treatment of adult and pediatric patients (6 years and older)
with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who
require basal (long-acting) insulin for the control of hyperglycemia.
LANTUS® SoloSTAR® is a disposable prefilled insulin pen. Needles and the Lantus® SoloSTAR® pen must not be shared.
LANTUS® MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. If mixed
or diluted, the solution may become cloudy, and the onset of action/time to peak
effect may be altered in an unpredictable manner.
LANTUS® is contraindicated in patients hypersensitive to insulin glargine or
the excipients.
Hypoglycemia is the most common adverse effect of insulin, including LANTUS®.
As with all insulins, the timing of hypoglycemia may differ among various insulin
formulations. Glucose monitoring is recommended for all patients with diabetes.
Any change of insulin type and/or regimen should be made cautiously and only under
medical supervision. Concomitant oral antidiabetes treatment may need to be adjusted.
Other adverse events commonly associated with LANTUS® include the following:
lipodystrophy, skin reactions (such as injection-site reaction, pruritus, rash),
and allergic reactions.
In clinical studies in adult patients there was a higher incidence of treatment-emergent
injection-site pain (2.7% LANTUS® vs 0.7% NPH). The reports of pain at the injection
site were usually mild and did not result in discontinuation of therapy.
Please click here for full prescribing information.
